Novel Biomarkers for Cardiovascular Diseases
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".
Deadline for manuscript submissions: 30 July 2024 | Viewed by 318
Special Issue Editor
Interests: ischemic stroke in diabetes; diabetic foot; Anderson-Fabry disease; cytokines
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In this Special Issue, several distinguished international authors will summarize the role of novel biomarkers for cardiovascular diseases.
Cardiovascular diseases (CVDs) still remain a major cause of morbidity and mortality worldwide, and their prevalence have been estimated to increase in the next years. In recent decades, both the prevalence and mortality of CVDs have exponentially increased in low- and middle-income countries. Furthermore, CVDs represent one of the most common comorbidities for several chronic diseases, including type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), and chronic obstructive pulmonary disease (COPD).
For these reasons, the use of biomarkers appears the most convenient option to screen and follow-up patients with CVDs in order to detect the possible cardiovascular risk trajectories in patients with ASCVD (Atherosclerotic Cardiovascular Disease) risk due to atherosclerosis and in patients with chronic disease involving organs other than the heart such as patients with chronic kidney disease (CKD) and chronic broncopulmonary disease such as chronic obstructive pulmonary diseases (COPDs), asthma, and interstitial lung diseases.
To our knowledge, none of the existing biomarkers for cardiovascular diseases are routinely used and scientifically validated among the general population and do not appear in the cardiovascular risk scores. Furthermore, the role of these proposed cardiovascular risk biomarkers has not been validated in the clinical setting of CKDs, in the clinical setting aiming to elucidate the possible response in terms of cardiovascular risk damage, and the clinical setting of chronic broncopulmonary diseases to elucidate the response to therapeutic strategies such as cardio and lung fitness.
This Special Issue will collect review articles and original investigations concerning the role of novel biomarkers of subclinical atherosclerosis such as the role of metabolomics in patients with peripheral and carotid atherosclerosis as a predictive factor of new vascular events.
Another theme will be the role of serum and epigenetic markers of inflammasome in subjects with atherosclerosis and end organ damage in organs such as heart, peripheral arteries, and aorta.
Another issue worthy of interest will be the role of novel biomarkers of congestive heart failure in subjects with heart failure and a reduced ejection fraction HFrEF and heart failure with a preserved ejection fraction (HFpEF).
No study has yet fully addressed the role of biomarkers in the cardiovascular risk prediction in subjects with COPD, asthma, and interstitial lung diseases. Chronic obstructive pulmonary disease (COPD) is a common but under-diagnosed disease. In COPD, there is an increased risk for concomitant cardiovascular disease, and cardiovascular comorbidity is associated with increased mortality. Still, patients with COPD may be less likely to receive cardiovascular preventative therapies, albeit most guidelines for the diagnosis and treatment of COPD include recommendations regarding the evaluation of cardiovascular risk factors and the presence of cardiovascular disease. However, no biomarker has been shown to identify subclinical cardiovascular disease in a representative population-based cohort of individuals with COPD, even though ischemic abnormalities on electrocardiogram (ECG) are suggested to be associated with worse prognosis.
In the cerebrovascular disease clinical setting, the role of possible biomarkers in the onset of new cerebrovascular events in subjects at high cerebrovascular risk still needs a substantial and extensive evaluation. A possible issue concerns the role of inflammatory, thrombotic, and epigenetic markers as possible diagnostic biomarkers in acute ischemic cerebrovascular events and as possible predictive variables in subjects at cerebrovascular risk.
Prof. Dr. Antonino Tuttolomondo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biomarker
- cardiovascular diseases
- congestive heart failure
- cardiorespiratory risk
- COPD
- stroke
- atherosclerosis
- inflammation
- thrombosis
- epigenetics
- microRNA
